Manufacturing · Profile from Manufacturing Research Companion: Companies, Strategic Moves, and Technical Studies
Danaher
The Washington, DC company that the brothers Steven and Mitchell Rales turned from a real-estate investment trust into a buyer of unglamorous US manufacturers in 1984 (from memory, verify), and then into one of the world's largest life-sciences and diagnostics groups — without ever being, at heart, anything other than an operating system that buys companies. Danaher's manufacturing story turns on process capability exported to each acquisition: the Danaher Business System (DBS), built from lean methods learned at its Jacobs Vehicle Systems (Jake Brake) unit in the late 1980s (from memory, verify), installed in every business it buys, from hand tools and test meters to centrifuges, filters and bioreactor bags. Danaher is also a serial separator: it spun off its industrial core as Fortive (completed 2 Jul 2016), its dental business as Envista (split-off completed 18 Dec 2019) and its water and product-identification business as Veralto (completed 30 Sep 2023) (SEC filings). What remained — Cytiva (bought from GE for ~$21.4bn, completed 31 Mar 2020), Pall, Beckman Coulter, Cepheid, Abcam and, from 10 Jun 2026, Masimo — is a consumables business whose "recurring" revenue proved cyclical in the 2023–24 bioprocessing destocking.
At a glance
- Founded
- 1984 as Danaher Corporation, from the Rales brothers' control of a real-estate investment trust (Diversified Mortgage Investors, from memory, verify); named after Danaher Creek in Montana (company lore, from memory, verify)
- Headquarters
- Washington, DC
- Ownership / structure
- Public (NYSE: DHR); the Rales brothers remain large shareholders and board members (from memory, verify current stakes)
- Leadership (2026)
- Rainer M. Blair, president and CEO since Sep 2020 (from memory, verify); Steven Rales, chairman (from memory, verify). Earlier CEOs: George Sherman (1990–2001), Larry Culp (2001–14, then GE CEO from 1 Oct 2018 — equal to General Electric), Tom Joyce (2014–20) (from memory, verify dates)
- Segments (2026)
- Biotechnology (Cytiva, Pall Life Sciences — bioprocessing and discovery), Life Sciences (Beckman Coulter Life Sciences, Leica Microsystems, SCIEX, Molecular Devices, IDT, Aldevron, Abcam and others), Diagnostics (Beckman Coulter Diagnostics, Cepheid, Radiometer, Leica Biosystems, and Masimo from Jun 2026) (company segment names; unit lists from memory, verify)
- Scale
- FY2025 (28 Jan 2026 release): revenue $24.6bn (+3.0%), non-GAAP core revenue +2.0%, operating cash flow $6.4bn, non-GAAP free cash flow $5.3bn, adjusted EPS $7.80 (+4.5%), adjusted operating margin 28.2%. Q3 2026 (21 Oct 2026): sales ~$6.6bn (~$6.55bn), core revenue +3.0% (+5.5% excluding respiratory testing), adjusted operating margin ~29%, adjusted EPS $2.11 (+11.5%); Diagnostics revenue $2,882m (+17.0% reported, flattered by Masimo); bioprocessing orders up mid-teens; 2026 adjusted EPS guidance raised to $8.57–8.62 (company release and call coverage, repo
- Plants
- Hundreds of plants worldwide inherited from acquisitions; bioprocess consumables (resins, filters, single-use bags and media) are made in a few dozen specialist sites in the US, Europe and Asia (company, verify counts)
- Signature moves (incl. failures)
- Founding and the first industrial buyouts (1984–86); DBS from Jake Brake (late 1980s); Fluke (1998); Beckman Coulter (2011); Pall (2015); the serial separations — Fortive, Envista, Veralto (2016–23); Cytiva (2020); the 2023–24 bioprocessing destocking and the Abcam purchase (2023); Masimo (2026)
9 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
1984
Rales Brothers Founding and Industrial Buyouts
Founding / acquisition (leveraged purchases of industrial companies through a listed vehicle)
1987
Danaher Business System from Jake Brake
Production-system change (lean transformation, then codification as a company-wide system)
1998
Fluke and the Instrument Platform
Acquisition (platform acquisition in electronic test and measurement)
2011
Beckman Coulter and the Diagnostics Pivot
Acquisition / strategy pivot (into clinical diagnostics at scale)
2015
Pall and Filtration
Acquisition (filtration and separation, incl. biopharma process filtration)
2016
Fortive Envista Veralto Serial Separations
Spin-off (Fortive, Veralto) and IPO plus split-off (Envista)
2020
Cytiva from GE Biopharma
Acquisition (carve-out from General Electric)
2023
Bioprocessing Destocking and Abcam
Demand shock (failure of forecasting and capacity timing) / acquisition (Abcam)
2026
Masimo Acquisition
Acquisition (patient monitoring and pulse oximetry into Diagnostics)